Dec 13 2014
Pharmacyclics, Inc. (NASDAQ: PCYC) today announced that it has been awarded BayBio's 2014 Pantheon DiNA™ Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA® (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.
BayBio, the Northern California affiliate of the Biotechnology Industry Association (BIO), represents 1,000 life sciences companies and institutions in Northern California. The Outstanding Company Award is given through an independent nomination and selection process to one company each year that has made the greatest advancement in and/or the greatest overall contribution to the Northern California life sciences industry in the prior year. Pharmacyclics was selected for the award due to its exceptional success with IMBRUVICA in a relatively short amount of time.
"We are honored to be recognized for the hard work and dedication of our team who made the rapid development and commercialization of IMBRUVICA possible," said Bob Duggan, Chairman & CEO, Pharmacyclics. "We also thank the clinicians with whom we partnered, the thousands of patients who have participated in our clinical trials, our strategic partner Janssen, and the U.S. Food and Drug Administration for the important roles they all have played so that we could bring forward such a transformative therapy in near record time."
IMBRUVICA received its first approval by the U.S. Food and Drug Administration (FDA) in November 2013 and has received two additional approvals within a nine-month period. In addition, IMBRUVICA was one of the first medicines to receive U.S. FDA approval via the new Breakthrough Therapy Designation pathway, and is the only product to have received three Breakthrough Therapy Designations. IMBRUVICA is already approved in 37 countries and a worldwide registration strategy is currently being pursued.
Pharmacyclics also was awarded the 2012 BayBio Pantheon DiNA Award for Outstanding Partnering.
IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, Inc.
Growth hormone-releasing hormone transforms therapeutic potential in health and chronic disease